Summary
Signal counts
Assets tracked: 2
Watchlist assets: 0
Registry stop assets: 0
Sponsor overview
Guangdong Association of Clinical Trials
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT07198841 | https://clinicaltrials.gov/study/NCT07416058
Assets
Linked programs
- IBI351 combined with cetuximab β: Low Signal (1/5)
- QL1706 (bispecific antibody targeting PD-1 and CLTA-4): Low Signal (1/5)